Morgan Stanley revised its earnings projections for Sinopharm Group (01099), reducing forecasts across 2025-2030 by 1%-6%. This adjustment reflects lowered sales expectations within both medical equipment and pharmaceutical distribution segments. Concurrently, the investment bank decreased its price target from HK$23 to HK$22.5 while reaffirming an Overweight stance on the stock. The recalibration signals cautious near-term sector outlook despite continued confidence in the company's strategic positioning.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.